This is a working overview of carcinogenicity, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
== Applications == Also known as cyclotetramethylene-tetranitramine, tetrahexamine tetranitramine, or octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine, HMX was first made in 1930. In 1949 it was discovered that HMX can be prepared by nitrolysis of RDX. Nitrolysis of RDX is performed by dissolving RDX in a 55% HNO3 solution, followed by placing the solution on a steambath for about six hours. HMX is used almost exclusively in military applications, including as the detonator in nuclear weapons, in the form of polymer-bonded explosive, and as a solid-rocket propellant. HMX is used in melt-castable explosives when mixed with TNT, which as a class are referred to as "octols". Additionally, polymer-bonded explosive compositions containing HMX are used in the manufacture of missile warheads and armor-piercing shaped charges. HMX is also used in the process of perforating the steel casing in oil and gas wells. The HMX is built into a shaped charge that is detonated within the wellbore to punch a hole through the steel casing and surrounding cement out into the hydrocarbon-bearing formations. The pathway that is created allows formation fluids to flow into the wellbore and onward to the surface. The Hayabusa2 space probe used HMX to excavate a hole in an asteroid in order to access material that had not been exposed to the solar wind. Ongoing research aims to reduce its sensitivity and improve some manufacturing properties.
== Etymology == in 1842 the English paleontologist Sir Richard Owen coined the term "dinosaur", using it to refer to the "distinct tribe or sub-order of Saurian Reptiles" that were then being recognized in England and around the world. The term is derived from Ancient Greek δεινός (deinos) 'terrible, potent or fearfully great' and σαῦρος (sauros) 'lizard or reptile'. Though the taxonomic name has often been interpreted as a reference to dinosaurs' teeth, claws, and other fearsome characteristics, Owen intended it also to evoke their size and majesty.
In electron ionization (EI), energetic electrons are produced by a hot cathode: a wire filament heated by running electric current through it, producing energetic electrons by thermionic emission. The electrons are then accelerated towards an anode. The voltage difference between the cathode and the anode determines the energy of the electron stream. Most organic compounds have ionization energy 8-15 eV, but empirically, the efficiency of ionization is too low unless the electron beam has an energy of 50-70 eV per electron. The spectral features, including fragmentation patterns, depend on the energy setting. Conventionally for EI, the electron energy is standardized to be exactly 70 eV. Consequently, if one wishes to compare their EI-MS results against standard databases, or produce results that can be added to standard databases, one must standardize their EI electron energy to 70 eV. EI accepts as input a stream of gas from the molecular leak. The gas stream crosses the electron stream perpendicularly. The collision ionizes the gas stream. The ion stream then is accerelated by a succession of electrodes. Typically an ion carrying 1 e would be accelerated to 1-10 keV. EI has many benefits for routine mass spectrometry of small organic molecules. It is cheap and robust, with reproducible spectrograms. Databases for EI spectrograms are widely available and covers many such molecules. EI is unsuited for large molecules, such as most biomolecules.
Sources: en.wikipedia.org
For example, the α decay of 239Pu to 235U can be used as an example of this procedure. with the assumption of a perfect purification time T0 then there will be a linear relationship between the in-growth of 235U and time elapsed since purification. There are, however, various instances where the correlation is not as clear. This strategy may not apply when the parent-daughter pair achieve secular equilibrium very rapidly or when the half-life of the daughter nuclide is significantly shorter than the time that has elapsed since purification of the nuclear material, e.g. 237Np/233Pa. Another possible complication is if in environmental samples, non-equivalent metal/ion transport for parents and daughter species may complicate or invalidate the use of chronometric measurements. Special age-dating relationships exist, including the commonly employed 234U/230Th and 241Pu/241Am chronometers. In special circumstances, parent-granddaughter relationships can be used to elucidate the age of nuclear materials when the material is intentionally made to look older through the addition of daughter nuclides. Chronometry is based on the concept that the composition of the nuclear material changes as samples are prepared and analyzed. This barrier can be substantial for species that decay quickly or whose daughter products put forth spectral interferences. The decay of 233U, for example, has a t1/2~1.6×105years which is rapid in comparison to many species and yield 229Th, which emits an α particle that is isoenergetic, having the same energy, as the parent.
=== Pharmacokinetics === RO5263397 has shown favorable pharmacokinetic properties for in vivo use based on its physicochemical properties and preclinical research. It is mainly metabolized by N-glucuronidation in humans. UGT2B10 polymorphisms can result in profoundly altered exposure to RO5263397 in humans. Implicated polymorphisms appear to be especially prevalent in people of African descent.
==== Absorption ==== The absolute bioavailability of suvorexant is 82% at a dose of 10 mg. Suvorexant exposure does not increase dose-proportionally over a dose range of 10 to 100 mg, which is likely due to decreased absorption at higher doses. Exposure to suvorexant increases by about 75% with a doubling of dose from 20 mg to 40 mg. The time to peak levels of suvorexant is 2 to 3 hours regardless of dose but with wide variation (range 30 minutes to 8 hours). Taking suvorexant with food does not modify suvorexant peak levels or area-under-the-curve levels (overall exposure) but does delay the time to peak concentrations by about 1.5 hours. Steady-state levels of suvorexant with once-daily continuous administration are reached within 3 days. Levels of suvorexant accumulate minimally, by about 1.2- to 1.6-fold, with repeated once-daily administration.
== History == As early as the 17th century, the Spanish used quinine from the bark of Cinchona trees to treat malaria after being shown the remedy from the Indigenous peoples of Peru, Bolivia, and Ecuador. In early 19th century India and other tropical posts of the British Empire, medicinal quinine was recommended to British officials and soldiers to prevent malaria, where it was mixed with soda and sugar to mask its bitter taste, creating tonic water. The first commercial tonic water was produced in 1858 when a new invention "An improved aerated liquid" known as Quinine Tonic Water was patented by the owner of Pitt & Co., Erasmus Bond and manufactured at their Wharf Road, City Road London factory. The mixed drink gin and tonic also originated in British colonial India, when the British mixed their medicinal quinine tonic with gin and other ingredients to make the bitter medicine more palatable. Soldiers in India were already given a gin ration, so the concoction was easy to make. In 1868, the first known record of a gin and tonic was in the Oriental Sporting Magazine and was described as a refreshing cocktail for spectators of horse racing, not as a medicine.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.